Schisandrin B inhibits TGF-β1-induced epithelial-mesenchymal transition in human A549 cells through epigenetic silencing of ZEB1

Exp Lung Res. 2019 May-Aug;45(5-6):157-166. doi: 10.1080/01902148.2019.1631906. Epub 2019 Jul 3.

Abstract

Purpose/Aim: More and more evidences suggest that airway remodeling of fibrotic lung diseases may be associated with epithelial-mesenchymal transition (EMT) of human A549 cells induced by transforming growth factor (TGF)-β1. Schisandrin B (Sch B) is the highest content of dibenzocyclooctadiene lignans in Schisandra chinensis. In this study, we assessed the inhibitory influences of Sch B on TGF-β1-stimulated EMT in human A549 cells. Materials and Methods: The influences of Sch B on cell viability, invasion and metastasis in TGF-β1-induced human A549 cells were detected by MTT, wound healing and transwell invasion assays. The expression levels of α-SMA, E-cadherin, ZEB1 and Twist1 were examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and western blot. The enrichment of H3K4me3 and H3K9me3 at the ZEB1 promoter was determined by ChIP analysis. Results: Experimental results showed that Sch B increased the expression of the epithelial phenotype marker E-cadherin and inhibited the expression of the mesenchymal phenotype marker α-SMA during EMT induced by TGF-β1. The enhancement in invasion and migration of TGF-β1-induced A549 cells was inhibited by Sch B. Sch B also repressed the expression of ZEB1 transcription factor in EMT, by increasing the enrichment of H3K9me3 at the ZEB1 promoter to repress its transcription while the expression of the Twist1 transcription factor was unaffected. Conclusions: Our data suggest that Sch B can prevent TGF-β1-stimulated EMT in A549 cells through epigenetic silencing of ZEB1, which may be clinically related to the efficient treatment of EMT-associated fibrotic diseases.

Keywords: Schisandrin B; ZEB1; epigenetic modifications; epithelial-mesenchymal transition; human A549 cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • A549 Cells
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / therapeutic use
  • Cyclooctanes / pharmacology
  • Cyclooctanes / therapeutic use
  • Drug Evaluation, Preclinical
  • Epigenesis, Genetic / drug effects
  • Epithelial-Mesenchymal Transition / drug effects*
  • Humans
  • Lignans / pharmacology*
  • Lignans / therapeutic use
  • Phytotherapy
  • Polycyclic Compounds / pharmacology*
  • Polycyclic Compounds / therapeutic use
  • Pulmonary Fibrosis / drug therapy*
  • Schisandra
  • Transforming Growth Factor beta1
  • Zinc Finger E-box-Binding Homeobox 1 / antagonists & inhibitors*

Substances

  • Antineoplastic Agents
  • Cyclooctanes
  • Lignans
  • Polycyclic Compounds
  • TGFB1 protein, human
  • Transforming Growth Factor beta1
  • ZEB1 protein, human
  • Zinc Finger E-box-Binding Homeobox 1
  • schizandrin B